Skip to content

Clinical trials

Sleep Initiation and Maintenance Disorders trials in Germany

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Sleep Initiation and Maintenance Disorders Country / region: Germany Clear all

51 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20042
20053
20063
20074
20082
20091
20101
20111
20121
20144
20151
20165
20173
20186
20191
20202
20212
20223
20232
20241
20252
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed42
Recruiting4
Terminated4
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Idorsia Pharmaceuticals Ltd.9
GlaxoSmithKline5
Sanofi5
ARCIM Institute Academic Research in Complementary and Integrative Medicine3
Janssen Research & Development, LLC3
Philipps University Marburg3
Eisai Inc.2
Midnight Pharma, LLC2
Biologische Heilmittel Heel GmbH1
Charite University, Berlin, Germany1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Sleep Initiation and Maintenance Disorders51
Parasomnias3
Sleep Wake Disorders3
Anxiety Disorders2
Sleep Apnea Syndromes2
Attention Deficit Disorder with Hyperactivity1
Breast Neoplasms1
Chronic Disease1
Chronic Pain1
Diabetes Mellitus1

Trials

Showing 76 to 51 of 51. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.